Documentos

A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)

Por

A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B) Read More »

Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive breast cancer: A Surveillance, Epidemiology, and End Results population‐based study

Por

Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive breast cancer: A Surveillance, Epidemiology, and End Results population‐based study Read More »

Receba nossa

Programação Semanal

Facebook Instagram Linkedin

Quem Somos

Como Produzir

Depoimentos

Fale Conosco

Termos e Condições

Lives
Cursos
Vídeos
Podcasts

Instituições
Profissionais
Grupos de estudo

Desenvolvido por makadu.group

Precisa de ajuda? Nos chame no chat da página!

Carrinho de compras